Xytis Pharmaceuticals Ltd.
This article was originally published in Start Up
Executive Summary
Xytis Pharmaceuticals Ltd., focused on in-licensing and developing late-stage CNS drug candidates, is taking a unique approach to treating schizophrenia by developing a drug that targets the NMDA receptor complex.